Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.
作者： Allah Detta , June Harland , Isma Hanif , S. Moira Brown , Garth Cruickshank
DOI: 10.1002/JGM.396
关键词:
摘要: Background The neurotropic herpes simplex virus mutant HSV1716 lacks the gene encoding virulence factor ICP34.5 and cannot replicate in nondividing cells where proliferating cell nuclear antigen (PCNA) is not actively engaged cellular DNA synthesis. In brain, tumoral expression of PCNA therefore confers on it oncolytic specificity may determine its efficacy. Three phase I trials glioma patients one metastatic melanoma have established that safe replicates selectively tumour tissue. Here we examine situ profiles common human brain tumours their vitro permissivity for replication to ascertain suitability therapy.
sci-hub.se 参考文章(17)
Maxine A. Farr-Jones, Ian F. Parney, Kenneth C. Petruk, Improved technique for establishing short term human brain tumor cultures. Journal of Neuro-oncology. ,vol. 43, pp. 1- 10 ,(1999) , 10.1023/A:1006115608103
David Kirn, Robert L. Martuza, James Zwiebel, Replication-selective virotherapy for cancer: Biological principles, risk management and future directions Nature Medicine. ,vol. 7, pp. 781- 787 ,(2001) , 10.1038/89901
Rona M MacKie, Barry Stewart, S Moira Brown, Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. The Lancet. ,vol. 357, pp. 525- 526 ,(2001) , 10.1016/S0140-6736(00)04048-4
J. Chou, J. J. Chen, M. Gross, B. Roizman, Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 10516- 10520 ,(1995) , 10.1073/PNAS.92.23.10516
Bruce P. Randazzo, Santosh Kesari, Richard M. Gesser, David Alsop, John C. Ford, S.Moira Brown, Alasdair Maclean, Nigel W. Fraser, Treatment of Experimental Intracranial Murine Melanoma with a Neuroattenuated Herpes Simplex Virus 1 Mutant Virology. ,vol. 211, pp. 94- 101 ,(1995) , 10.1006/VIRO.1995.1382
V Papanastassiou, R Rampling, M Fraser, R Petty, D Hadley, J Nicoll, J Harland, R Mabbs, M Brown, The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Therapy. ,vol. 9, pp. 398- 406 ,(2002) , 10.1038/SJ.GT.3301664
Nikolai Rainov, Christof Kramm, Vector delivery methods and targeting strategies for gene therapy of brain tumors. Current Gene Therapy. ,vol. 1, pp. 367- 383 ,(2001) , 10.2174/1566523013348445
R Rampling, G Cruickshank, V Papanastassiou, J Nicoll, D Hadley, D Brennan, R Petty, A MacLean, J Harland, E McKie, R Mabbs, M Brown, Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Therapy. ,vol. 7, pp. 859- 866 ,(2000) , 10.1038/SJ.GT.3301184
W D Hunter, C A Palmer, F Feigenbaum, C Tornatore, F Tufaro, R L Martuza, J M Markert, M D Medlock, S D Rabkin, G Y Gillespie, T Todo, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy. ,vol. 7, pp. 867- 874 ,(2000) , 10.1038/SJ.GT.3301205
A. Detta, E. Hitchcock, Rapid estimation of the proliferating index of brain tumours. Journal of Neuro-oncology. ,vol. 8, pp. 245- 253 ,(1990) , 10.1007/BF00177357